Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia

NCT03796390 is registered in ClinicalTrials.gov with Hebei Senlang Biotechnology Inc., Ltd. as lead sponsor.

NCT NCT03796390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03796390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia
Lead sponsor
Hebei Senlang Biotechnology Inc., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
December 26, 2018
Completion date
June 6, 2021
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelocytic leukemia